Ambion raises $10.5 million for RNA applications:
This article was originally published in Clinica
Ambion has raised $10.5m in equity financing from investors led by Telegraph Hill Partners of San Francisco, California. Austin, Texas-based Ambion develops RNA-based products for molecular diagnostics and life science research. Its ribonuclease-resistant RNA assays and SNP detection technology is already licensed by diagnostics companies in the fields of HIV and hepatitis C detection, and in urine screening for bladder cancer.